Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 9 minute read General news updates LiveOne (Nasdaq: LVO) raises 2026 cost savings target to $7.5m as AI replaces headcount across all subsidiaries LiveOne raises 2026 cost target to $7.5M using Anthropic Claude and OpenAI, cutting staff to 78. Read our full strategic analysis. bySrinathMarch 19, 2026